What is low-dose naltrexone?
Naltrexone is an FDA-approved medicine that has been in clinical use for decades. At its labeled 50 mg dose it blocks opioid receptors around the clock, which is why it is approved for alcohol dependence and for blocking administered opioids. Low-dose naltrexone, or LDN, means taking a small fraction of that, usually 1 to 5 mg daily, with 4.5 mg the most studied dose.
It is one of the more interesting drug-repurposing stories in medicine: at a tiny dose, the same molecule appears to stop being an opioid blocker in any practical sense and to start behaving like something else entirely, a modulator of inflammation in the nervous system. Because no company markets a low-dose tablet, LDN is prepared by compounding pharmacies, and every use described here is off-label.
How is it thought to work?
Two mechanisms anchor the current model. The first involves glial cells, the immune cells of the brain and spinal cord. Overactive glial signaling is linked to persistent pain, and low doses of naltrexone appear to dampen that inflammatory signaling through a receptor pathway called TLR4. In plain terms: where chronic pain has a neuroinflammatory engine, LDN is thought to turn the engine down rather than mask the signal.
The second mechanism runs through the opioid receptor itself. A brief nightly blockade, rather than a continuous one, appears to prompt the body to upregulate its own opioid signaling, a rebound in the endorphin system. Both mechanisms come mostly from laboratory and animal work, which is worth knowing: the model is coherent and biologically plausible, and it has not been directly demonstrated in people.
Why it matters
Chronic pain, fatigue, and inflammatory conditions are exactly the territory where conventional options are hardest: opioids create their own problems, anti-inflammatories wear on the gut and kidneys, and many patients cycle through drugs without relief. A medicine that is inexpensive, taken once daily by mouth, well tolerated over a full year of trial exposure, and aimed at neuroinflammation rather than symptom masking is a genuinely attractive proposition. That is why LDN has such a devoted following among patients and clinicians treating stubborn chronic conditions.
The honest counterweight is that enthusiasm has run ahead of the trial record, and this article keeps the two carefully separate.
What it is used for
The FDA label carries no indication for chronic pain, fibromyalgia, inflammatory bowel disease, or multiple sclerosis, so every application here is off-label use of an approved drug. In practice, clinicians prescribe LDN across a striking range: fibromyalgia and other chronic pain, autoimmune and neuroimmune conditions, inflammatory bowel disease, skin conditions, and post-infectious syndromes such as long COVID. A 2026 review found 105 published studies across those areas, of which only 15 were randomized controlled trials; the rest are mostly case reports and small feasibility studies.
Fibromyalgia carries the deepest evidence, with four randomized placebo-controlled trials, and it is where the story gets specific below. Strong Craft Regen does not prescribe, compound, or supply low-dose naltrexone; this page is educational.
What people notice in practice
What patients and prescribing clinicians commonly report, labeled honestly as experience rather than trial evidence, is a slow settling rather than a switch flipping: pain that grinds a little less over weeks, steadier energy, better mornings. Vivid dreams are the most reproducible side effect in the trials, and users mention them constantly; nausea shows up too. Plenty of people report no change at all.
The pattern is consistent with the trial record, where individual responses spread widely around a small average difference. If there are strong responders, the current trials were not designed to find them, and the recent reviews propose exactly that kind of study next.
The pros and the cons
What's promising
- An approved medicine with decades of clinical use and a well-understood safety profile.
- Inexpensive, oral, once daily, and well tolerated: across twelve months of trial exposure, adverse events roughly matched placebo.
- Pooled analyses of the fibromyalgia trials show a modest benefit on pain over placebo.
- A plausible mechanism aimed at neuroinflammation, a driver conventional painkillers do not touch.
What's uncertain
- The three largest fibromyalgia trials each found no significant advantage over placebo on their pain endpoints.
- For most conditions where LDN is prescribed, no controlled trial has been run at all.
- The trials enrolled women only and measured self-reported scores, so other populations and objective endpoints are untested.
- No two large trials shared a dose and duration, so the best regimen is unknown.
Worth considering
- One absolute rule: naltrexone cannot be combined with opioid medicines, opioid dependence, or acute withdrawal. It can precipitate withdrawal, and lost opioid tolerance makes a later resumed dose dangerous.
- Compounded quality varies by pharmacy; a reputable compounder matters.
- Expect vivid dreams early; most other effects are mild and transient.
- The most recent review is blunt: where LDN is used, its experimental status should be explained up front. We agree.
Why the evidence lags the practice
Naltrexone is an old generic, and 1 to 5 mg strengths are compounded preparations rather than patentable products, so no company has a commercial reason to fund a large trial. The trials that exist were paid for by hospitals, universities, and non-profit foundations. That is the whole explanation for why a medicine this widely prescribed has this thin a record: nobody owns it.
Keep the two kinds of unknown separate. In fibromyalgia, large trials ran and found no advantage over placebo, which is a result about the regimens tested. In most other conditions where LDN is used, no controlled trial has ever run, which is not a result at all. Untested is not the same as tested and found wanting.
What the key trials tested
Our framing rule for evidence: a trial tests one dose, one schedule, one population, one endpoint. First, where the LDN evidence sits:
Preclinical & practice
Most conditions where LDN is prescribed: case reports and small pilots only.
Early trials
Crohn's disease, multiple sclerosis, post-COVID fatigue, complex regional pain syndrome.
Late-stage trials
Fibromyalgia: four randomized placebo-controlled trials, one lasting a full year.
Approved uses
Naltrexone 50 mg: alcohol dependence and opioid blockade. LDN itself: none.
And the trials that matter most:
- The early momentum came from two small Stanford studies: a 10-woman pilot and a 31-woman crossover in which pain fell 28.8% on LDN against 18% on placebo. Their authors called the evidence preliminary and asked for bigger parallel-group trials.
- Those bigger trials then ran, and each missed its pain endpoint: a 58-patient Danish crossover in 2023, the 99-woman FINAL trial in 2024 at 6 mg for twelve weeks, and the 98-woman INNOVA trial in 2026 at 4.5 mg for a full year. In each, the placebo group improved too, and the difference between arms was small.
- Pooled analyses that combine all the fibromyalgia trials still find a modest benefit on pain over placebo, weighted by the small early studies. The broadest analysis across chronic pain generally, mixing conditions and comparators, found no significant overall difference.
- In Crohn's disease, a Cochrane review found only two small trials to pool, 46 people in total: remission rates did not differ significantly, some secondary measures favored LDN, and the certainty was rated low throughout.
- In multiple sclerosis, two 2010 trials measured quality of life: one reported a mental-health gain, the other found no meaningful differences, and neither measured relapses or disability progression.
- No two of the large fibromyalgia trials shared a dose and a duration, and doses above 6 mg, combination protocols, men, and objective endpoints remain untested.
Every study behind this article is filterable in our research library on the Science page.
Questions people ask
Is low-dose naltrexone FDA approved?
Naltrexone itself is FDA approved, at 50 mg, for alcohol dependence and for blocking administered opioids. The low-dose use is off-label, and because no low-dose tablet is marketed, 1 to 5 mg doses are prepared by compounding pharmacies. Off-label prescribing of an approved drug is legal and common; it simply means the evidence bar the label represents has not been met for that use.
Is LDN safe, and who should never take it?
Tolerability in the trials was good: across twelve weeks and even twelve months, adverse events roughly matched placebo, with vivid dreams the most reproducible effect and nausea next. The hard rule is opioids: anyone taking opioid pain medicines, anyone opioid-dependent including on methadone or buprenorphine, and anyone in acute withdrawal must not take naltrexone. It can precipitate withdrawal, and because opioid tolerance falls during treatment, resuming a previously tolerated opioid dose afterward can be life-threatening. That is screened for before any prescription.
Does LDN work for fibromyalgia?
The honest answer is a real maybe with shrinking room. Two small early trials were positive, the three largest and best-masked trials each found no significant advantage over placebo on pain, and pooled analyses still show a modest average benefit driven by the early studies. Individual responses spread widely, and studies designed to identify possible strong responders are what the field is calling for next.
Why does my pharmacy have to compound it?
The only marketed strength is a 50 mg tablet, so a 1 to 5 mg daily dose has to be made to order by a compounding pharmacy. Quality varies more between compounders than between manufacturers of an approved product, which makes the choice of pharmacy a real part of the decision.
What to take away
If you remember five things from this article, make them these:
- LDN is a tiny, compounded, off-label dose of an approved decades-old medicine, aimed at calming neuroinflammation rather than masking pain.
- It is inexpensive, oral, and well tolerated over a year of trial exposure, with vivid dreams the most consistent side effect.
- The fibromyalgia record is mixed and honest reading matters: small early trials positive, the three largest individually null, pooled analyses modestly favorable.
- For most other uses, no controlled trial exists at all, which is a funding fact about an unpatentable generic as much as a scientific verdict.
- The opioid contraindication is absolute, and any trial of LDN belongs under a clinician who knows your full medication list.
The evidence
Selected references, each verified against primary sources (PubMed, ClinicalTrials.gov, and FDA labeling). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Low-Dose Naltrexone (LDN) is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.